Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion type Assertion NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_head.
- NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion description "[Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_provenance.
- NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion evidence source_evidence_literature NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_provenance.
- NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion SIO_000772 15946589 NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_provenance.
- NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion wasDerivedFrom befree-2016 NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_provenance.
- NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_assertion wasGeneratedBy ECO_0000203 NP498641.RApBMhE4OTmgbcrBAV-OX9-UFlO2B9u145YnvERENROBA130_provenance.